首页> 美国卫生研究院文献>Kidney International Reports >Ombitasvir Paritaprevir Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

【2h】

Ombitasvir Paritaprevir Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

机译：肾脏病患者的OmbitasvirParitaprevirRitonavir和达沙布韦含或不含利巴韦林

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionPatients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment.

机译：简介丙型肝炎病毒（HCV）感染和慢性肾脏疾病（CKD）的患者是高度优先治疗的人群。

著录项

期刊名称 Kidney International Reports
作者
David E. Bernstein; Albert Tran; Paul Martin; Kris V. Kowdley; Marc Bourliere; Mark S. Sulkowski; Paul J. Pockros; Boris Renjifo; Deli Wang; Diana L. Shuster; Daniel E. Cohen; Ira M. Jacobson;
展开▼
作者单位

展开▼
年(卷),期 2019(4),2
年度 2019
页码 245–256
总页数 12
原文格式 PDF
正文语种
中图分类泌尿科学（泌尿生殖系疾病）;小儿泌尿科学;肾疾病;
关键词
chronic hepatitis C chronic kidney disease direct-acting antiviral hepatitis C virus;

机译：慢性丙型肝炎;慢性肾脏病;直接作用抗病毒药;丙型肝炎病毒;

相似文献

外文文献
中文文献
专利

1. Ombitasvir, Paritaprevir, Ritonavir, and?Dasabuvir With or Without Ribavirin in?Patients With Kidney Disease [J] . David E. Bernstein, Albert Tran, Paul Martin, Kidney International Reports . 2019,第2期

机译：肾病患者是否使用奥比他韦，帕瑞他韦，利托那韦和达沙布韦伴或不伴利巴韦林
2. Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin Pharmacokinetics in HCV-Infected Subjects with Chronic Kidney Disease Stage 4 (Severe Renal Impairment) or Stage 5 (End-Stage Renal Disease) [J] . Shuster Diana L., Menon Rajeev M., Ding Bifeng, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：HCV感染受试者的ImbItasvir，Paritavir，Ritonavir，Dasabuvir和利巴韦林药代动力学，慢性肾病第4阶段（重肾损伤）或第5阶段（末期肾病）
3. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia [J] . Ligita Jancoriene, Katazyna Polubenko, Edita Kazenaite, Hepatitis Monthly . 2018,第1期

机译：直接作用抗病毒药物Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir联合或不联合利巴韦林在C型肝炎病毒（HCV）基因型1中感染的未接受过治疗或有治疗经验的患者是否患有肝硬化：立陶宛和拉脱维亚的真实生活
4. The Natural History of Chronic Kidney Disease Revisited-A 72-Month Mayo Health System Hypertension Clinic Practice-Based Research Network Prospective Report on End-Stage Renal Disease and Death Rates in 100 High-Risk Chronic Kidney Disease Patients: A Call for Circumspection [C] . Macaulay A.C. Onuigbo Conference on Peritoneal Dialysis . 2009

机译：慢性肾病的自然历史重新审议-A 72个月的MASO卫生系统高血压诊所的研究网络网络前期肾病和死亡率100个高危慢性肾病患者的死亡率：一个呼吁守则
5. Impact of a challenge intervention on weight control in pediatric patients with kidney disease and diabetes: A retrospective analysis of patient records. [D] . Sanderson, Lori. 2010

机译：挑战性干预对小儿肾脏疾病和糖尿病患者体重控制的影响：患者记录的回顾性分析。
6. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials [O] . Jason Grebely, Massimo Puoti, Heiner Wedemeyer, 2018

机译：Ombitasvir / Paritaprevir / Ritonavir和Dasabuvir联合或不联合利巴韦林在接受阿片类药物替代治疗的慢性丙型肝炎病毒基因型1感染患者中的疗效和安全性：对12项临床试验的事后分析
7. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia [O] . Ligita Jancoriene, Katazyna Polubenko, Edita Kazenaite, 2018

机译：直接作用抗病毒药虫/ paritabrevir / ritonavir + dasabuvir在丙啶病毒（hcv）基因虫中（hcv）基因型1-感染的治疗 - 幼稚或治疗 - 经验丰富的患者或没有肝硬化的患者：立陶宛和拉脱维亚的现实生活经验

Ombitasvir Paritaprevir Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

摘要

著录项

相似文献

相关主题

期刊订阅